康泰生物（300601）(300601.SZ)披露2025年年度业绩预告，公司预计归属于上市公司股东的净利润 4900万元至7300万元，同比下降63.80%至75.70%;扣除非经常性损益后的净利润5150万元至7650万元， 同比下降68.90%至79.06%。 ...

证券日报网讯 1月29日，百奥赛图发布2025年年度业绩预盈公告称，公司预计2025年年度归属于母公司 所有者的净利润16，242.86万元到18，242.86万元，与上年同期相比，将增加12，888.68万元到14， 888.68万元，同比增加384.26%到443.88%。 （文章来源：证券日报） ...

Core Viewpoint - ST Unimed has announced an annual performance forecast indicating a projected net loss attributable to shareholders of the listed company for 2025, estimated between 55 million to 90 million yuan [1] Financial Performance - The expected net profit, excluding non-recurring gains and losses, is projected to be a loss of 70 million to 105 million yuan for the year 2025 [1] - The primary reason for the losses is the suspension of production and sales by its subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd., which has significantly impacted related business revenue [1] Operational Challenges - The company is actively working on rectification measures to expedite the resumption of production, but ongoing costs and expenses continue to contribute to the losses [1]

诺唯赞(688105.SH)发布公告，公司预计2025年度实现归属于母公司所有者的净利润-2000万元至-1000万 元。 ...

ST未名公告，预计2025年度净利润亏损5500万元-9000万元，上年同期亏损1.37亿元。公司业绩亏损主 要原因为控股子公司天津未名生物医药有限公司暂停生产和销售，相关业务收入受到影响。同时，为推 进复产进程，公司积极整改，成本与费用支出持续，导致亏损。 ...

2025年，中国疫苗出口到了全球85个市场。 沃森生物（300142.SZ）在1月28日晚间发布的2025年业绩预告中表示，公司国内疫苗产品收入降幅收 窄，趋于平稳，国外疫苗产品收入持续增长，出口疫苗产品收入较上年同期增长约35%。 不过，中国疫苗企业在加大出口的过程中，如何获得更高利润回报，目前仍有待发力。相较2024年疫苗 出口金额靠价格驱动的增长，2025年的出口更多还是靠量取胜。2025年，疫苗出口量增幅高达 130.54%，显示出"量增价跌"的趋势。 长期以来，国内许多疫苗企业聚焦成熟度高且市场风险较小的传统技术路线产品，Me-too（同类仿创） 类管线占比高，且大多集中在宫颈癌疫苗、肺炎球菌疫苗和脑膜炎球菌疫苗等热门疫苗品种，重磅产品 上市时间显著晚于欧美头部企业，进而导致国内疫苗存量市场竞争持续加剧、产品同质化竞争日益明 显。 面对国内疫苗市场竞争愈演愈烈背景下，越来越多的中国疫苗企业加大力度往外走，一些企业借助"一 带一路"沿线国家产业合作机遇，加大海外发展中国家或地区的市场布局力度。在"一带一路"国家中， 不少发展中国家缺乏疫苗生产能力，这给中国疫苗企业出海发展带来机遇。 康泰生物（3006 ...

Core Viewpoint - The company, Dize Pharmaceutical, is pursuing a listing on the Hong Kong Stock Exchange to enhance its global strategy, improve its international brand image, and strengthen its core competitiveness, rather than solely for fundraising purposes [1]. Group 1 - The company has successfully completed a targeted private placement and is now planning to issue H-shares [1]. - The primary goal of the Hong Kong listing is to deepen the company's global strategic layout and attract international investors [1]. - The company aims to leverage the advantages of dual listings to facilitate cooperation and communication with multinational pharmaceutical companies [1].

Core Viewpoint - Watson Bio expects to achieve revenue of 2.4 billion to 2.43 billion yuan and a net profit attributable to shareholders of 160 million to 190 million yuan in 2025, reflecting a year-on-year growth of 13% to 34% [2] Group 1: Financial Performance - The company anticipates a narrowing decline in domestic vaccine product revenue and continuous growth in international vaccine product revenue, with export vaccine revenue increasing by approximately 35% compared to the previous year [2] - Operational management capabilities have improved due to ongoing cost reduction and efficiency enhancement measures, contributing to the growth in net profit [2] Group 2: International Expansion - By the end of 2025, Watson Bio's vaccine products have been exported to 24 countries and regions, with a successful entry into the Latin American market for its core product, the 23-valent pneumonia vaccine [2] - The company is advancing over 30 international product registration projects covering around 20 countries, including core products like pneumonia and HPV vaccines, laying a solid foundation for sustained overseas revenue growth [2] Group 3: Innovation and R&D - Watson Bio maintains a high level of investment in innovative vaccine research and development, collaborating with renowned universities and research institutions to integrate resources and accelerate the development of multiple innovative vaccines [4] - The company has established an mRNA vaccine technology platform in collaboration with Fudan University and Shanghai Bluebird Biopharmaceuticals, with several mRNA vaccines receiving clinical trial approval [3][4] - The competitive nature of the vaccine industry necessitates continuous strengthening of core technological barriers and operational optimization through an "innovation + management" dual-drive model [4]

Core Viewpoint - Yifang Bio (688382) is expected to report a net profit attributable to shareholders of -292 million yuan for 2025, with projected operating revenue of 37.2452 million yuan, which is below 100 million yuan [1] Group 1: Financial Performance - The company anticipates a net loss of 292 million yuan for 2025 [1] - Projected operating revenue for 2025 is 37.2452 million yuan, which excludes unrelated business income and income without commercial substance [1] - The expected revenue is significantly lower than 100 million yuan [1] Group 2: Business Operations - The company has maintained high levels of R&D investment during the reporting period based on overall R&D progress for 2025 [1] - Current operating revenue primarily comes from licensing and collaboration, with variations in revenue composition from year to year [1] - The income from technology licensing and collaboration is not sufficient to cover costs and expenses, leading to continued losses in 2025 [1] Group 3: Competitive Position - Despite the anticipated losses, the company's core business and competitive strengths have not experienced significant adverse changes [1]

康泰生物表示，因四联苗受百白破免疫程序调整、营业成本上升及研发投入增加等因素影响，致使2025 年度净利润较上年同期下降。 北京商报讯（记者 丁宁）1月29日晚间，康泰生物（300601）发布2025年业绩预告显示，预计2025年实 现归属净利润为4900万元—7300万元，较上年同期下降63.8%—75.7%。 ...